The Conversation (0)
PBR reports AstraZeneca has agreed to acquire Omthera Pharmaceuticals along with novel dyslipidemia treatment in a deal, which has a total potential cost of nearly $443m.
PBR reports AstraZeneca (NYSE:AZN, LSE:AZN) has agreed to acquire Omthera Pharmaceuticals (NASDAQ:OMTH) along with novel dyslipidemia treatment in a deal, which has a total potential cost of nearly $443m.
As quoted in the market news:
AstraZeneca chief executive officer Pascal Soriot said, “Epanova offers real potential both as a distinctive monotherapy for the treatment of hypertriglyceridemia and in combination with Crestor for patients at high risk of adverse cardiovascular events.”